评价项目 | 观察组30例 | 对照组30例 | ||
治疗前 | 治疗后 | 治疗前 | 治疗后 | |
PF | 15.21 ± 3.13 | 20.56 ± 2.32*# | 15.18 ± 3.20 | 18.34 ± 2.56* |
RP | 4.19 ± 0.41 | 5.91 ± 0.22*# | 4.23 ± 0.36 | 5.89 ± 0.25* |
SF | 4.33 ± 1.71 | 6.32 ± 1.68*# | 4.36 ± 1.69 | 5.45 ± 1.37* |
BP | 3.79 ± 1.15 | 5.28 ± 1.3*# | 3.82 ± 1.19 | 4.31 ± 1.37* |
MH | 9.61 ± 2.18 | 14.62 ± 1.53*# | 9.56 ± 2.23 | 10.79 ± 1.81* |
RE | 3.89 ± 0.56 | 5.31 ± 0.46*# | 3.93 ± 0.56 | 4.65 ± 0.39* |
VT | 8.78 ± 2.34 | 11.33 ± 1.89*# | 8.75 ± 2.31 | 9.96 ± 1.65* |
GH | 8.83 ± 1.23 | 13.35 ± 0.89*# | 8.78 ± 1.34 | 10.13 ± 0.86* |